FDA gets expanded Power to prevent Medical Device Supply Disruptions
Due to the Corona pandemic, there were supply shortages of medical device products in the USA. To get these shortages under control in the future, the FDA gets expanded power. What is planned?
First of all, financial resources are being allocated for a supply shortage prevention program. That's as much as $21.6 million the U.S. has budgeted for the Resilient Supply Chain and Shortages Prevention Program (RSCSPP) in fiscal year 2022. The program runs in conjunction with the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). The focus is on strengthening the nation's supply chains, including becoming less dependent on medical devices manufactured outside the United States. For that purpose, preventive measures need to be taken. For example, potential supply chain disruptions of medical devices need to be identified and the continuous monitoring of supply chains needs to be established to be able to intervene quickly. To this end, FDA capabilities are to be further strengthened.
Please see the FDA Website to find further information.
Related GMP News
21.01.2025FDA Warning Letter Statistics on Medical Devices in the past Fiscal Year
21.01.2025Artificial Intelligence in Medical Devices - Notified Bodies' Point of View
21.01.2025New FDA Guidance on Risk Analyses for Drugs, Biologics and Combination Products
08.10.2024EMA updates Question and Answer Document on Combination Products
08.10.2024Transparency Guidelines for Medical Devices with Artificial Intelligence
12.09.2024Notified Body Survey on Certificates & Applications under the Medical Devices/IVD Regulation